USV Launches Xenia Brand Range Following Empagliflozin Patent Expiry

The Xenia portfolio comprises five key products designed to address varied treatment needs. It includes Xenia 10, containing Empagliflozin 10 mg, and Xenia 25, containing Empagliflozin 25 mg as monotherapy options. Additionally, the range offers Xenia M 12.5/500, combining Empagliflozin 12.5 mg with Metformin 500 mg, and Xenia M 12.5/1000 ER, which pairs Empagliflozin 12.5 mg with Metformin 1000 mg in an extended-release form. The brand range also includes Xenia ST 25, a fixed dose combination of Empagliflozin 25 mg with Sitagliptin 100 mg.

The Xenia range has been introduced across different price points. Xenia 10 is priced at ₹125 per pack, Xenia 25 at ₹163.9, Xenia M 12.5/500 at ₹140, Xenia M 12.5/1000 ER at ₹165, and Xenia ST 25 at ₹220.2.

Commenting on the launch, Prashant Tewari, Managing Director, USV said, “India has over 101 million people with Type 2 diabetes and 136 million with prediabetes. With Xenia, we aim to expand access to modern diabetes care.”

With the loss of exclusivity, Empagliflozin and its combinations are now available at significantly reduced prices, enhancing affordability. USV’s extensive reach across metros, Tier I, II & III cities, corporate hospitals, and e-pharmacies ensures Xenia's accessibility nationwide, including rural areas.